Citable filing context

VEEV filing events and research context

Server-rendered

VEEV's research view summarizes recent SEC filing context, starting with mda_quarterly from Jun 5, 2026.

VEEV filing events and research context
FiledItemContext
Jun 5, 2026mda_quarterlyVeeva Systems continues to demonstrate steady growth as a provider of industry cloud solutions for the life sciences sector, with total revenue for the quarter ended April 30, 2026, reaching $883 million, a 16% increase year-over-year. The company’s revenue model is heavily weighted toward subscriptions, which accounted for 83% of total revenue. Operations are divided into Commercial Solutions and R&D and Quality Solutions, with the latter representing 55% of total revenue and expected to grow as a percentage of the business. Financial performance is driven by expanding usage among existing customers and annual price adjustments. While subscription gross margins remain strong at 86%, professional services margins have compressed to 20% due to increased headcount investments. Operating expenses are primarily driven by personnel costs, as the company continues to scale its R&D and sales organizations. Veeva maintains a robust liquidity position with $7.3 billion in cash and short-term investments. The company is utilizing this capital to fund operations, strategic acquisitions—such as the recent purchase of Ostro—and a $2 billion share repurchase program, under which $221 million was deployed during the quarter. Management notes that seasonal billing patterns make the first quarter the strongest for cash inflows.
Mar 20, 2026businessVeeva is a Public Benefit Corporation providing industry cloud solutions for the global life sciences sector, including pharmaceutical, biotechnology, and MedTech companies. Its offerings are organized into four primary categories: Development Cloud (clinical, regulatory, and safety), Quality Cloud (QMS and lab solutions), Commercial Cloud (sales, marketing, and medical affairs), and Data Cloud (reference and longitudinal patient data). A critical strategic transition is underway as the company migrates from Salesforce-based Veeva CRM to its proprietary Vault CRM, with legacy support ending December 31, 2029. Veeva is further evolving its platform by integrating agentic AI agents into the Veeva Vault ecosystem to enhance productivity and data quality. Serving 1,552 customers, including global leaders like Novartis and Eli Lilly, the company complements its software with professional services and strategic business consulting. Key competitive threats include Salesforce and IQVIA, particularly within the CRM and data analytics markets. Operations are subject to stringent regulatory frameworks, including FDA 21 CFR and GDPR, and the company relies on a growing portfolio of patents to protect its intellectual property against competitors and non-practicing entities.
Nov 21, 2025mda_quarterlyVeeva Systems continues to demonstrate strong financial performance, reporting total revenue of $811.2 million for the quarter ended October 31, 2025, a 16% year-over-year increase. Growth is driven by its two primary segments: Commercial Solutions (Veeva Commercial Cloud and Data Cloud) and R&D Solutions (Veeva Development and Quality Clouds). R&D Solutions remains the larger contributor, accounting for 55% of total revenue for the nine-month period, a trend management expects to continue. Revenue growth is primarily fueled by expanding usage among existing customers and annual inflation-based price adjustments. While the company maintains a robust customer base of 1,477, it notes that many R&D clients are smaller, pre-commercial entities, introducing potential volatility regarding long-term retention. Operationally, the company is scaling headcount to support product development and service demand, which has increased employee-related costs. Infrastructure expenses, particularly for hosting services like Amazon Web Services and Salesforce, also rose due to higher user volume. Liquidity remains strong with $6.6 billion in cash and short-term investments. Cash flow from operations benefited significantly from the One Big Beautiful Bill Act (OBBBA), which restored immediate expensing for domestic R&D expenditures. Management expects this tax change to continue bolstering operating cash flows in future periods.

Source: SEC EDGAR filing text and events; period Jun 5, 2026; filed Jun 5, 2026.

Continue research

Keep researching VEEV

Follow same-sector companies and source explainers connected to the research view.

Browse Health Care

Related tickers

LLY
Lilly (Eli)
$1.02T
Health Care
Open company page →
JNJ
Johnson & Johnson
$558.88B
Health Care
Open company page →
ABBV
AbbVie
$393.91B
Health Care
Open company page →
UNH
UnitedHealth Group
$369.32B
Health Care
Open company page →
MRK
Merck & Co.
$295.00B
Health Care
Open company page →
AZN
ASTRAZENECA PLC
$281.75B
Health Care
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →